Frontiers in Aging
Cure8 research brief
Ulcerative colitis (UC) in the elderly: diagnostic and therapeutic considerations
Pediatrics and family
Vedolizumab
Steroids
Anti-TNF
Anti Integrin
Colonoscopy
Weight Loss
Abdominal Pain
Why This Matters
Older adults with UC face different risks and treatment trade-offs than younger patients — higher infection and cancer risks, medication toxicities, and challenges with diagnosis and colonoscopy. Understanding these differences helps tailor safer, more effective care.
Who Should Pay Attention
Older adults with ulcerative colitis, caregivers and family members, gastroenterologists, geriatricians, and clinicians managing IBD medication and perioperative risk.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This review discusses ulcerative colitis in people aged 60 and older, highlighting age-related biological changes (immunosenescence, SASP, dysbiosis, mitochondrial dysfunction) that may alter disease presentation and healing.
It summarizes common clinical features in older adults (more left-sided disease, anemia, weight loss, less abdominal pain) and diagnostic challenges such as poorer bowel prep and broader differential diagnoses.
Regarding treatment, the article notes 5-aminosalicylic acid (mesalamine) remains first-line but requires renal monitoring; systemic steroids carry higher infection and osteoporosis risk; thiopurines (e.g., azathioprine) are limited by myelotoxicity and malignancy concerns; and vedolizumab has a more favorable safety profile than anti-TNF agents in older patients.
The authors recommend multidisciplinary care that addresses multimorbidity, polypharmacy, nutrition, and mental health to reduce high-risk surgery. The review is grounded in the article abstract and appears to synthesize clinical considerations rather than report a new trial or primary data.
It is intended as a clinical overview to inform treatment choice and risk assessment in older adults with UC.
Keep In Mind
This article is a review-style clinical discussion (abstract-level content). It summarizes age-related mechanisms and practical management considerations rather than reporting new trial results. Recommendations should be interpreted in the context of individual patient factors and current clinical guidelines.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationFrontiers in Aging
PublisherFrontiers Media SA
AuthorsŁucja Wróbel, Ewa Małecka-Wojciesko
Study typeJournal Article
Indexed viaCrossref
Source typeResearch paper
PublishedAug 4, 2026, 12:00 AM
Content availableJournal abstract
Funding disclosed by the source: Uniwersytet Medyczny w Lodzi, award 503/1-002-01/503-11-001
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Autologous Stem Cell Transplant for Crohn's Disease
This trial is testing whether adding vedolizumab after autologous stem cell transplant can improve remission rates for people with severe Crohn's disease that has failed multiple therapies.
DYNAMIC-UC: Early qFIT and Calprotectin Change Predicting Relapse in Biologic-Naive Ulcerative Colitis
Early changes in stool tests (qFIT and fecal calprotectin) might help predict which biologic‑naive ulcerative colitis patients will relapse or need escalation to biologic/JAK therapy. If validated, such markers could...
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
People with IBD sometimes are excluded from or uncertain about immune checkpoint inhibitor cancer trials because of concerns about triggering autoimmune flares. This trial explicitly studies safety and disease impact in...